搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
STAT
13 小时
With promising early data in triple negative breast cancer, a new bispecific heats up
New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...
ENDPOINTS NEWS
18 小时
BioNTech reports early survival data for VEGF bispecific, weeks after buy ...
BioNTech shared survival data from a Phase 1b/2 trial testing BNT327 (PD-L1xVEGF bispecific) plus nab-paclitaxel in ...
4 天
Regeneron: Recent Bear Run May Be Justified - Pharma Faces A Testing 2025
Regeneron Pharmaceuticals, Inc.'s stock faces challenges with Eylea's decline but potential growth from Dupixent. Find out ...
5 天
Lung cancer symptom that shows in fingers and often goes ignored
Whilst a persistent cough and coughing up blood is a sign something is wrong, another symptom that's often forgotten about is ...
5 天
Lesser-know lung cancer symptom that you can see in your fingers
Eminem's mum, Debbie Nelson, died at the age of 69 this week and was was previously diagnosed with lung cancer.
C&EN
6 天
Why Chinese biotech is attracting more global attention
The Chinese pharmaceutical industry has a reputation abroad as a supplier of active pharmaceutical ingredients invented ...
8 天
OncoC4 Announces FDA Clearance of IND Application for Potential Best-in-Class PD-1/VEGF ...
AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...
8 天
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to ...
Citadel ended September with 91% fewer Palantir shares, despite the stock's eye-popping gains, after selling about 5.2 ...
9 天
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.
Pharmabiz
12 天
China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab
China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...
manilatimes
13 天
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab ...
Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈